Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

PaperCitations, authors & open-access status

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,499 citations, 2009 year and closed oa status.

1,499